Late Preclinical (High Risk High Volume Late Translational) Projects

The aim of this funding line is to close the translational research gap, that is, to promote the translation of findings from basic research into clinical applications. Once proof of concept has been established, researchers can apply for funds to develop their therapeutic or diagnostic principle and bring it closer to clinical application (first-in-man or first-in-patient studies). These late translational projects constitute an important building block in the DZHK strategy.

Shared Expertise Projects

Cooperative projects based on Shared Expertise provide an excellent means of enabling concrete experimental high-risk projects while at the same time intensifying collaboration between the partner sites. The special scientific skills, expertise and infrastructure of one DZHK partner are made available to DZHK partners in other locations in a transparent and uncomplicated manner (see also Shared Expertise). Expertise that typically can be shared include animal models, vectors and OMICs technologies as well as stem cell-based models of human diseases. By promoting Shared Expertise the DZHK aims to avoid using DZHK funds to acquire or develop infrastructure that already exists in other DZHK institutions. Moreover, these mainly small, bilateral projects are intended to support early translation of experimental hypotheses.

Shared Expertise projects 2014

Using the zebrafish as a model, researchers gain important insights into diseases of the heart.

Cooperations with External Partners

The DZHK also funds small preclinical research projects in cooperation with external partners. The advantage of this is that Germany’s entire expertise in cardiovascular research can be used by members of the DZHK whilst allowing the DZHK to involve external partners in DZHK research projects. External partners are universities, university hospitals and non-university institutes who are NOT member institutions of the DZHK.

Cooperations with Industry

Frequently, the translation of new diagnostic or therapeutic principles into clinical practice can only be achieved with the help of industrial partners. When it comes to searching for suitable active substances by means of high-throughput screening or optimising target structures or even clinical studies, the pharmaceutical industry and biotechnology companies have unique conditions and competencies. Therefore, the DZHK has declared its intention to enter into strategic alliances with industrial partners. 

The DZHK is currently conducting formal negotiations with an industrial partner, but would also be interested in cooperating with additional partners. Intellectual property (IP) issues, in particular, have to be carefully negotiated and regulated in such cooperative partnerships.